Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature
- PMID: 17043710
- PMCID: PMC1578545
Spurious hypocalcemia after gadodiamide-enhanced magnetic resonance imaging: a case report and review of the literature
Abstract
Gadolinium-enhanced magnetic resonance imaging is a diagnostic modality widely used in urologic practice. We report on a 54-year-old woman in whom a critically low serum calcium level was measured with standard colorimetric assay after gadodiamide-enhanced magnetic resonance imaging. The same phenomenon was noted in 2 other patients seen in our practice. Repeat serum calcium measurements performed several hours later were within normal limits. Commercially available gadolinium-based contrast agents might precipitate critically low serum calcium values when measured by standard colorimetric assay. Physician awareness of gadodiamide-induced spurious hypocalcemia might prevent unnecessary therapeutic interventions.
Similar articles
-
Spurious hypocalcemia after gadodiamide administration.Mayo Clin Proc. 2005 Dec;80(12):1655-7. doi: 10.4065/80.12.1655. Mayo Clin Proc. 2005. PMID: 16342660
-
Gadodiamide administration causes spurious hypocalcemia.Radiology. 2003 Jun;227(3):639-46. doi: 10.1148/radiol.2273012007. Radiology. 2003. PMID: 12773671
-
Effects of gadopentetate dimeglumine and gadodiamide on serum calcium, magnesium, and creatinine measurements.J Magn Reson Imaging. 2006 Mar;23(3):383-7. doi: 10.1002/jmri.20517. J Magn Reson Imaging. 2006. PMID: 16463306
-
Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. doi: 10.1097/00004424-199303001-00004. Invest Radiol. 1993. PMID: 8486501 Review.
-
Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.Fundam Clin Pharmacol. 2006 Dec;20(6):563-76. doi: 10.1111/j.1472-8206.2006.00447.x. Fundam Clin Pharmacol. 2006. PMID: 17109649 Review.
Cited by
-
Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval.Cureus. 2020 Aug 11;12(8):e9668. doi: 10.7759/cureus.9668. Cureus. 2020. PMID: 32923263 Free PMC article.
-
A review of drug-induced hypocalcemia.J Bone Miner Metab. 2009;27(6):635-42. doi: 10.1007/s00774-009-0119-x. J Bone Miner Metab. 2009. PMID: 19730969 Review.
References
-
- Tombach B, Bremer C, Reimer P, et al. Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology. 2001;218:651–657. - PubMed
-
- Runge VM. Safety of magnetic resonance contrast media. Top Magn Reson Imaging. 2001;12:309–314. - PubMed
-
- Prince MR, Arnoldus C, Frisoli JF. Nephrotoxicity of high-dose gadolinium compared to iodinated contrast. J Magn Reson Imaging. 1996;6:162–166. - PubMed
-
- Muroff LR. MRI contrast: current agents and issues. Appl Radiol. 2001;30(suppl):5–7.
-
- Prince MR. More on pseudohypocalcemia and gadolinium-enhanced MRI. N Engl J Med. 2004;350:87–88. - PubMed
Publication types
LinkOut - more resources
Full Text Sources